References
- Appleton R.E., Rainford N.E.A., Gamble C., Messahei S., Humphreys A., Hickey H. et al. Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT. Health Technology Assessment, 2020, 2020 (58), 1–96. doi: 10.3310/hta24580
- Arrigo A., Raiteri U., Ardizzone G. Levetiracetam monotherapy for treatment of partial status epilepticus in a patient following a liver transplant. Epilepsia, 2004, 2004 (Suppl. 3), 145.
- Chakravarthi S., Goyal M.K., Modi M., Bhalla A., Singh P. Levetriacetam versus phenytoin in management of status epilepticus. Journal of Clinical Neuroscience, 2015, 2015, 959–963. doi: 10.1016/j.jocn.2014.12.013.
- Chamberlain J.M., Kapur J., Shinnar S., Elm J., Holsti M., Babcock L. Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomized controlled trial. Lancet, 2020, 2020 (10231), 1217–1224. doi: 10.1017/S01406736(20)30611–5.
- Dalziel S.R., Borland M.L., Furyk J., Bonisch M., Neutze J., Donath S. et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (Con-SEPT): an open-labe, multicentre, randomized controlled trial. Lancet, 2019, 2019 (10186): 2135–2145. doi 10.1016/S01406736(19)30722–6
- Gujjar A.R., Nandhagopal R., Jacob P.C., Al-Hashim A., Al-Amrani K., Ganguly S.S. et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. Seizure: European Journal of Epileptology, 2017, 2017, 8–12. doi: 10.1016/j.seizure.2017.05.001
- Handral A., Veerappa B.G., Gowda S.K., Benakappa N., Benakappa A. Levetiracetam versus Fosphenytoin in pediatric convulsive status epilepticus: a randomized controlled trail. Journal of Pediatric Neurosciences, 2020, 2020, 252–256. doi: 10.4103/jpn.JPN_109_19
- Kapur J., Elm J., Chamberlain J.M., Barsan W., Cloyd J., Lowenstein D. et al. Randomized trial of three anticonvulsant medications for status epilepticus. New England Journal of Medicine, 2019, 2019, 2103–2113. doi: 10.1056/NEJMoal1905795
- Lyttle M.D., Rainford N.E.A., Gamble C., Messahel S., Humphreys A., Hickey H. et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet, 2019, 2019 (10186), 2125–2134. doi: 10.1016/S01406736(19)30724-x
- Misra U.K., Kalita J., Maurya P.K. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labelled pilot study. Journal of Neurology, 2012, 2012, 645–648. doi: 10.1007/s00415-011-6227-2
- Mundlamuri R.C., Sinha S., Subbakrishna D.K., Prathyusha P.V., Nagappa M., Bindu P.S. et al. Management of generalised convulsive status epilepticus (SE): A prospective randomized controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam – Pilot study. Epilepsy Research, 2015, 2015, 52–58. doi: 10.1016/j.eplepsyres.2015.04.013
- Nalisetty S., Kandasamy S., Sridharan B., Vijayakumar V., Sangaralingam T., Krishnamoorthi N. Clinical effectiveness of Levetiracetam compared to Fosphenytoin in the treatment of benzodiazepine refractory convulsive status epilepticus. The Indian Journal of Pediatrics, 2020, 2020, 512–519. doi: 10.1007/s12098-020-03221-2
- Navarro V., Dagron C., Elie C., Lamhaut L., Demeret S., Urien S. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonacepam in status epilepticus (SAMUKeppra): a randomized, double-blind, phase 3 trial. Lancet Neurology, 2016, 2016, 47–55. doi: 10.1016/S1474-442(15)00296-3
- Nazir M., Rayees A.T., Asimi R., Syed W.A. Comparative efficacy of IV phenytoin, IV valproate, and IV levetiracetam in childhood status epilepticus. Journal of Epilepsy Research, 2020, 2020, 69–73. doi: 10.14581/jer.20011
- Nene D., Mundlamuri R.C., Satishchandra P., Prathyusha P.V., Nagappa M., Bindu P.S. et al. Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with genralized convulsive status epilepticus (GCSE): A prospective randomized controlled pilot study. Seizure: European Journal of Epileptology, 2019, 2019, 111–117. doi: 10.1016/j.seizure.2019.01.015
- Nicolas J.-M., Hannestad J., Holden D., Kervyn S., Nabulsi N., Tytgat D. et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia, 2016, 2016, 201–209. doi: 10.1111/epi.13267
- Noureen N., Khan S., Khursheed A., Iqbal I., Maryam M., Sharib S.M. et al. Clinical efficacy and safety of injectable levetiracetam versus phenytoin as second-line therapy in the management of generalized convulsive status epilepticus in children: an open-label randomized controlled trial. Journal of Clinical Neurology, 2019, 2019, 468–472. doi: 10.3988/jcn.2019.15.4.468
- Redecker J., Wittstock M., Rösche J. The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined? Epilepsy & Behavior, 2017, 71, 35–38. doi: 10.1016/j.yebeh.2017.03.18
- Rösche J., Dudek M., Teleki A., Godau J., Bösel J. Levetiracetam in der Behandlung des Status Epilepticus – ein update. Fortschritte der Neurologie – Psychiatrie, 2019, 2019, 357–363. doi: 10.1055/a-0832-8652
- Rösche J., Pohley I., Rantsch K., Walter U., Benecke R. Erfahrungen mit Levetiracetam in der Behandlung des Status epilepticus. Fortschritte der Neurologie – Psychiatrie, 2013, 2013, 21–27. doi: 10.1055/s-0032-1312951
- Rosenow F., Weber J.R. Dohmen C., Hamer H.M., Holtkamp M., Jahnke K. et al. Status epilepticus im Erwachsenenalter, S2k-Leitlinie, 2020. In: Deutsche Gesellschaft für Neurologie (ed.), Leitlinien für Diagnostik und Therapie in der Neurologie. On-line: www.dgn.org/leitlinien (last visit May 2nd 2021).
- Sathe A.G., Elm J.J., Cloyd J.C., Chamberlain J.M., Silbergleit R., Kapur J. et al. The association of patients weight and dose of fosphenytoin, levetiracetam, and valproic acid with treatment success in status epilepticus. Epilepsia, 2020, 2020, e66–e70. doi: 10.111/epi.16534
- Vignesh V., Rameshkumar R., Mahadevan S. Comparison of Phenytoin, Valproate and Levetiracetam in Pediatric convulsive status epilepticus: A randomized double-blind controlled clinical trial. Indian Pediatrics, 2020, 2020, 222–227.
- Wani G., Imram A., Dhawan N., Gupta A., Giri J.I. Levetiracetam versus phenytoin in children with status epilepticus. Journal of Family Medicine and Primary Care, 2019, 2019, 3367–3371. doi: 10.4103/jfmpc.jfmpc_750_19
- Wongjirattikarn R., Sawanyawisuth K., Pranboon S., Tiamkao S., Tiamkao S. Can generic intravenous levetiracetam be used for acute repetitive convulsive seizure or status epilepticus? A randimized controlled trial. Neurology and Therapy, 2019, 2019, 425–431. doi: 10.1007/s40120-019-00150-x
- Yasiry Z., Shorvon S.D. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: A meta-analysis of published studies. Seizure, 2014, 2014, 167–174. doi: 10.1016/j.seizure.2013.12.007